Results 101 to 110 of about 32,416 (217)
Development of Streptococcus pneumoniae Vaccines Using Live Vectors [PDF]
: Streptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular ...
core +1 more source
Abstract Background Effectively identifying individuals exposed to drug underuse, overuse and potentially inappropriate medication (PIM) in older adults is essential for minimizing preventable drug‐related harms. Methods We analysed data from 54,296 individuals aged 60–74 years from the German National Cohort (NAKO).
Miriam Degen +18 more
wiley +1 more source
Recombinant plants provide a new approach to the production of bacterial polysaccharide for vaccines. [PDF]
Bacterial polysaccharides have numerous clinical or industrial uses. Recombinant plants could offer the possibility of producing bacterial polysaccharides on a large scale and free of contaminating bacterial toxins and antigens.
G. C. Whitelam (7665758) +58 more
core +1 more source
BACKGROUND: The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV) in August 2009 and switched to 13-valent PCV in April 2011. In April 2009 monovalent hepatitis B and combined Diphtheria-Tetanus-Pertussis and Haemophilus influenzae type
Lowe-Jallow, Y +6 more
core +1 more source
State of pneumococcal vaccine immunity
Like the other invasive encapsulated bacteria, Streptococcus pneumoniae is also covered with a polysaccharide structure. Infants and elderly are most vulnerable to the invasive and noninvasive diseases caused by S. pneumoniae. Although antibodies against
Mustafa Akkoyunlu
doaj +1 more source
Immunization plays a crucial role in protecting children from life-threatening conditions such as pneumococcal disease. Pneumococcal disease can affect multiple organ systems and manifest as an invasive or noninvasive disease.
Vijay Yewale +4 more
doaj +1 more source
Multivalent pneumococcal vaccines have been developed successfully to combat invasive pneumococcal diseases (IPD) and reduce the associated healthcare burden.
James Z. Deng +10 more
doaj +1 more source
Age at First RSV Hospitalisation and the Risk of Subsequent Bacterial Pneumonia
Acta Paediatrica, Volume 115, Issue 6, Page 1298-1300, June 2026.
Samuel Videholm +4 more
wiley +1 more source
Since the introduction of the 7-valent vaccine, invasive pneumococcal disease have greatly decreased; however, changes in the distribution of pneumococcal serotypes have recently highlighted the need for vaccines with wider coverage.
Valleriani, Claudia +22 more
core +1 more source
BACKGROUND: In a previous UK multi-center randomized study 278 children received three doses of 7-valent (PCV-7) or 13-valent (PCV-13) pneumococcal conjugate vaccine at 2, 4 and 12 months of age.
Trück, J +50 more
core +1 more source

